Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements.
COVID-19
hepatitis B
hepatitis C
infection
lupus
pneumocystis
tuberculosis
vaccine
Journal
International journal of rheumatic diseases
ISSN: 1756-185X
Titre abrégé: Int J Rheum Dis
Pays: England
ID NLM: 101474930
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
28
03
2021
accepted:
18
04
2021
pubmed:
18
5
2021
medline:
15
7
2021
entrez:
17
5
2021
Statut:
ppublish
Résumé
Systemic lupus erythematosus (SLE) is a more common autoimmune rheumatic disease in the Asia-Pacific region. The prognosis of SLE remains unsatisfactory in some Asian countries because of delayed diagnosis, limited access to medications, increased complications and issues of tolerability and adherence to treatment. The Asia-Pacific League of Associations for Rheumatology SLE special interest group has recently published a set of consensus recommendations on the management of SLE for specialists, family physicians, specialty nurses, and other healthcare professionals in the Asia-Pacific region. This article reports a systematic literature review of the infective complications of SLE in Asia and evidence for prevention of these infections by pre-emptive antimicrobial therapy and vaccination.
Identifiants
pubmed: 33999518
doi: 10.1111/1756-185X.14125
doi:
Substances chimiques
Anti-Infective Agents
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
880-895Informations de copyright
© 2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
Références
Oku K, Atsumi T. Systemic lupus erythematosus: nothing stale her infinite variety. Mod Rheumatol. 2018;28(5):758-765.
Morand EF. Systemic lupus erythematosus: stress and the onset of SLE. Nat Rev Rheumatol. 2018;14(3):127-128.
Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020;21(6):605-614.
Barbhaiya M, Costenbader KH. Environmental exposures and the development of systemic lupus erythematosus. Curr Opin Rheumatol. 2016;28(5):497-505.
Lee YH, Choi SJ, Ji JD, Song GG. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 2016;25(7):727-734.
Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745.
Gordon C, Amissah-Arthur M-B, Gayed M, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: executive summary. Rheumatology. 2018;57(1):14-18.
Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64(6):797-808.
Tunnicliffe DJ, Singh-Grewal D, Kim S, Craig JC, Tong A. Diagnosis, monitoring, and treatment of systemic lupus erythematosus: a systematic review of clinical practice guidelines. Arthritis Care Res. 2015;67(10):1440-1452.
Kasitanon N, Louthrenoo W, Sukitawut W, Vichainun R. Causes of death and prognostic factors in Thai patients with systemic lupus erythematosus. Asian Pac J Allergy Immunol. 2002;20(2):85-91.
Wang Z, Li M, Wang Y, et al. Long-term mortality and morbidity of patients with systemic lupus erythematosus: a single-center cohort study in China. Lupus. 2018;27(5):864-869.
Mok CC, Yap DYH, Navarra SV, et al. Overview of lupus nephritis management guidelines and perspective from Asia. Int J Rheum Dis. 2013;16(6):625-636.
Yin X, Kim K, Suetsugu H, et al. Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus. Ann Rheum Dis. 2020;80(5):632-640
Hamijoyo L, Candrianita S, Rahmadi AR, et al. The clinical characteristics of systemic lupus erythematosus patients in Indonesia: a cohort registry from an Indonesia-based tertiary referral hospital. Lupus. 2019;28(13):1604-1609.
Mok CC, Tse SM, Chan KL, Ho LY. Prevalence and risk factors of herpes zoster infection in patients with biopsy proven lupus nephritis undergoing immunosuppressive therapies. Lupus. 2020;29(8):836-844.
Mok CC, Hamijoyo L, Kasitanon N, et al. The Asia Pacific League of Associations for Rheumatology (APLAR) Consensus Statements on the Management of Systemic Lupus Erythematosus. Lancet Rheumatol. 2021; in press.
Watanabe R, Ishii T, Nakamura K, et al. Prevalence and time course of hepatitis B virus infection in patients with systemic lupus erythematosus under immunosuppressive therapy. Mod Rheumatol. 2013;23(6):1094-1100.
Gendelman O, Mahroum N, Comaneshter D, et al. Hepatitis B carrier state among SLE patients: case-control study. Immunol Res. 2017;65(1):257-261.
Lin WT, Chen YM, Chen DY, et al. Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study. Lupus. 2018;27(1):66-75.
Lu CL, Tsai ST, Chan CY, et al. Hepatitis B infection and changes in interferon-alpha and -gamma production in patients with systemic lupus erythematosus in Taiwan. J Gastroenterol Hepatol. 1997;12(4):272-276.
Sui M, Wu R, Hu X, et al. Low prevalence of hepatitis B virus infection in patients with autoimmune diseases in a Chinese patient population. J Viral Hepat. 2014;21(12):925-929.
Zhao J, Qiu M, Li M, Lu C, Gu J. Low prevalence of hepatitis B virus infection in patients with systemic lupus erythematosus in southern China. Rheumatol Int. 2010;30(12):1565-1570.
Chen X, Hong L, Zhang W, et al. Hepatitis B virus infection rate and distribution in Chinese systemic lupus erythematosus patients. Med Sci Monit. 2015;21:1955-1959.
Thong BY, Koh ET, Chng HH, Chow WC. Outcomes of chronic hepatitis B infection in Oriental patients with rheumatic diseases. Ann Acad Med Singap. 2007;36(2):100-105.
Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations. World J Gastroenterol. 2015;21(36):10274-10289.
Tse KC, Yung S, Tang C, Yip TP, Chan TM. Management of hepatitis B reactivation in patients with lupus nephritis. Rheumatol Int. 2009;29(11):1273-1277.
Dong HJ, Ni LN, Sheng GF, Song HL, Xu JZ, Ling Y. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis. J Clin Virol. 2013;57(3):209-214.
Kim SJ, Hsu C, Song YQ, et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group. Eur J Cancer. 2013;49(16):3486-3496.
Chen YM, Chen HH, Huang WN, et al. Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: a long-term, real-world observation. Int J Rheum Dis. 2019;22(6):1145-1151.
Kuo MH, Tseng CW, Lee CH, Tung CH, Tseng KC, Lai NS. Moderate risk of hepatitis B virus reactivation in HBsAg(-)/HBcAb(+) carriers receiving rituximab for rheumatoid arthritis. Sci Rep. 2020;10(1):2456.
Chen MH, Chen MH, Liu CY, et al. Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment. J Infect Dis. 2017;215(4):566-573.
Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT, American Gastroenterological Association I. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215-219; quiz e16-7.
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398.
Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1-98.
Mahroum N, Hejly A, Tiosano S, et al. Chronic hepatitis C viral infection among SLE patients: the significance of coexistence. Immunol Res. 2017;65(2):477-481.
Chen M-H, Chen M-H, Tsai C-Y, et al. Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy. Lupus. 2015;24(10):1029-1036.
Mitwalli AH, Hayat A, Alwakeel J, Hammad D. Effects of concomitant hepatitis C virus infection in patients with underlying lupus nephritis on long-term renal outcome. Nephrol Dial Transplant. 2012;27(2):627-632.
Organization WH. Global tuberculosis report 2020: executive summary 2020. https://apps.who.int/iris/bitstream/handle/10665/337538/9789240016095-eng.pdf
Ahmmed MF, Islam MN, Ferdous S, Azad AK, Ferdous N. Tuberculosis in systemic lupus erythematosus patients. Mymensingh Med J. 2019;28(4):797-807.
Tam LS, Li EK, Wong SM, Szeto CC. Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scand J Rheumatol. 2002;31(5):296-300.
Yun JE, Lee SW, Kim TH, et al. The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol. 2002;20(2):127-132.
Erdozain JG, Ruiz-Irastorza G, Egurbide MV, Martinez-Berriotxoa A, Aguirre C. High risk of tuberculosis in systemic lupus erythematosus? Lupus. 2006;15(4):232-235.
Sayarlioglu M, Inanc M, Kamali S, et al. Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization. Lupus. 2004;13(4):274-278.
Shyam C, Malaviya AN. Infection-related morbidity in systemic lupus erythematosus: a clinico-epidemiological study from northern India. Rheumatol Int. 1996;16(1):1-3.
Mok MY, Lo Y, Chan TM, Wong WS, Lau CS. Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy. J Rheumatol. 2005;32(4):609-615.
Lao M, Chen D, Wu X, et al. Active tuberculosis in patients with systemic lupus erythematosus from Southern China: a retrospective study. Clin Rheumatol. 2019;38(2):535-543.
Bhattacharya PK, Jamil M, Roy A, Talukdar KK. SLE and tuberculosis: a case series and review of literature. J Clin Diagn Res. 2017;11(2):OR01-OR3.
Palavutitotai N, Buppajarntham T, Katchamart W. Etiologies and outcomes of pleural effusions in patients with systemic lupus erythematosus. J Clin Rheumatol. 2014;20(8):418-421.
Victorio-Navarra ST, Dy EE, Arroyo CG, Torralba TP. Tuberculosis among Filipino patients with systemic lupus erythematosus. Semin Arthritis Rheum. 1996;26(3):628-634.
Li JC, Fong W, Wijaya L, Leung YY. Disseminated tuberculosis masquerading as a presentation of systemic lupus erythematosus. Int J Rheum Dis. 2018;21(1):352-355.
Bharath G, Kumar P, Makkar N, et al. Mortality in systemic lupus erythematosus at a teaching hospital in India: a 5-year retrospective study. J Family Med Prim Care. 2019;8(7):2511-2515.
Pattanaik SS, Muhammed H, Chatterjee R, et al. In-hospital mortality and its predictors in a cohort of SLE from Northern India. Lupus. 2020;29(14):1971-1977.
Yilmaz N, Zehra Aydin S, Inanc N, Karakurt S, Direskeneli H, Yavuz S. Comparison of QuantiFERON-TB Gold test and tuberculin skin test for the identification of latent Mycobacterium tuberculosis infection in lupus patients. Lupus. 2012;21(5):491-495.
Gaitonde S, Pathan E, Sule A, Mittal G, Joshi VR. Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Ann Rheum Dis. 2002;61(3):251-253.
Monnet X, Vidal-Petiot E, Osman D, et al. Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Crit Care. 2008;12(1):R28.
Morris A, Norris KA. Colonization by Pneumocystis jirovecii and its role in disease. Clin Microbiol Rev. 2012;25(2):297-317.
Morris A, Lundgren JD, Masur H, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis. 2004;10(10):1713-1720.
Godeau B, Coutant-Perronne V, Le Thi HD, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol. 1994;21(2):246-251.
Murray SG, Schmajuk G, Trupin L, et al. National lupus hospitalization trends reveal rising rates of herpes zoster and declines in pneumocystis pneumonia. PLoS One. 2016;11(1):e0144918.
Kapoor TM, Mahadeshwar P, Nguyen S, et al. Low prevalence of Pneumocystis pneumonia in hospitalized patients with systemic lupus erythematosus: review of a clinical data warehouse. Lupus. 2017;26(14):1473-1482.
Kim T, Sung H, Chong YP, et al. Low lymphocyte proportion in bronchoalveolar lavage fluid as a risk factor associated with the change from trimethoprim/sulfamethoxazole used as first-line treatment for Pneumocystis jirovecii pneumonia. Infect Chemother. 2018;50(2):110-119.
Weng C-T, Liu M-F, Weng M-Y, et al. Pneumocystis jirovecii pneumonia in systemic lupus erythematosus from southern Taiwan. J Clin Rheumatol. 2013;19(5):252-258.
Yeo K-J, Chen H-H, Chen Y-M, et al. Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study. BMC Infect Dis. 2020;20(1):112.
Narata R, Wangkaew S, Kasitanon N, Louthrenoo W. Community-acquired pneumonia in Thai patients with systemic lupus erythematosus. Southeast Asian J Trop Med Publ Health. 2007;38(3):528-536.
Kadoya A, Okada J, Iikuni Y, Kondo H. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol. 1996;23(7):1186-1188.
Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis. 2018;77(5):644-649.
Zhang Y, Zheng Y Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases. Rheumatol Int. 2014;34(12):1765-1771.
Fei Y, Shi X, Gan F, et al. Death causes and pathogens analysis of systemic lupus erythematosus during the past 26 years. Clin Rheumatol. 2014;33(1):57-63.
Kokubu H, Kato T, Nishikawa J, Tanaka T, Fujimoto N. Adverse effects of trimethoprim-sulfamethoxazole for the prophylaxis of Pneumocystis pneumonia in dermatology. J Dermatol. 2021;48(4):542-546
Buganu A, Atta M, Solomon M, Banerjee PR, Ganti L. Stevens Johnson syndrome initiated by an adverse reaction to trimethoprim-sulfamethoxazole. Cureus. 2020;12(8):e10023.
Soejima M, Sugiura T, Kawaguchi Y, et al. Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosus. Arthritis Res Ther. 2007;9(2):R23.
Suyama Y, Okada M, Rokutanda R, et al. Safety and efficacy of upfront graded administration of trimethoprim-sulfamethoxazole in systemic lupus erythematosus: a retrospective cohort study. Mod Rheumatol. 2016;26(4):557-561.
Maezawa R, Kurasawa K, Arai S, Okada H, Owada T, Fukuda T. Positivity for anti-RNP antibody is a risk factor for adverse effects caused by trimethoprim-sulfamethoxazole, a prophylactic agent for P. jiroveci pneumonia, in patients with connective tissue diseases. Mod Rheumatol. 2013;23(1):62-70.
Kitazawa T, Seo K, Yoshino Y, et al. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. J Infect Chemother. 2019;25(5):351-354.
Ice LL, Barreto JN, Dao BD, et al. Relationship of sulfamethoxazole therapeutic drug monitoring to clinical efficacy and toxicity: a retrospective cohort study. Ther Drug Monit. 2016;38(3):319-326.
Yang DH, Xu Y, Hong L, Song ZY, Ge WH. Efficacy of caspofungin combined with clindamycin for Pneumocystis jirovecii pneumonia in a systemic lupus erythematosus patient: a case report and literature review. Respir Med Case Rep. 2019;26:108-111.
De Stefano JA, Myers JD, Du Pont D, Foy JM, Theus SA, Walzer PD. Cell wall antigens of Pneumocystis carinii trophozoites and cysts: purification and carbohydrate analysis of these glycoproteins. J Eukaryot Microbiol. 1998;45(3):334-343.
Annaloro C, Della Volpe A, Usardi P, Lambertenghi DG. Caspofungin treatment of Pneumocystis pneumonia during conditioning for bone marrow transplantation. Eur J Clin Microbiol Infect Dis. 2006;25(1):52-54.
Hof H, Schnulle P Pneumocystis jiroveci pneumonia in a patient with Wegener's granulomatosis treated efficiently with caspofungin. Mycoses. 2008;51(Suppl 1):65-67.
Wang ZG, Liu XM, Wang Q, Chen NF, Tong SQ. A retrospective study of patients with systemic lupus erythematosus combined with Pneumocystis jiroveci pneumonia treated with caspofungin and trimethoprim/sulfamethoxazole. Medicine. 2019;98(23):e15997.
Pope J, Jerome D, Fenlon D, Krizova A, Ouimet J. Frequency of adverse drug reactions in patients with systemic lupus erythematosus. J Rheumatol. 2003;30(3):480-484.
Taqi SA, Zaki SA, Nilofer AR, Sami LB. Trimethoprim-sulfamethoxazole-induced Steven Johnson syndrome in an HIV-infected patient. Indian J Pharmacol. 2012;44(4):533-535.
Mahmood SB, Abou ZZ. Systemic lupus erythematosus triggered by trimethoprim-sulfamethoxazole. Scand J Rheumatol. 2020;49(6):507-508.
Petri M, Allbritton J. Antibiotic allergy in systemic lupus erythematosus: a case-control study. J Rheumatol. 1992;19(2):265-269.
Chen C, Yao B, Yan M, Su KE, Wang H, Xu C. The plight of patients with lupus nephritis during the outbreak of COVID-19 in Wuhan, China. J Rheumatol. 2020;47(9):1452.
Cho J, Kandane-Rathnayake R, Louthrenoo W, et al. COVID-19 infection in patients with systemic lupus erythematosus: data from the Asia Pacific Lupus Collaboration. Int J Rheum Dis. 2020;23(9):1255-1257.
Goyal M, Patil P, Pathak H, et al. Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India. Ann Rheum Dis. 2020.
Teh CL, Cheong YK, Wan Musa WR, Wan Mohd Akbar SA, Mat Husin N, Gun SC. COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine. Ann Rheum Dis. 2021;80(5):e69.
Rathi M, Singh P, Bi HP, et al. Impact of the COVID-19 pandemic on patients with systemic lupus erythematosus: observations from an Indian inception cohort. Lupus. 2021;30(1):158-164.
Chuah SL, Teh CL, Wan Mohd Akbar SA, Cheong YK, Singh Sachdev Manjit B. Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic. Ann Rheum Dis. 2020; in press.
Guven F, Ogul H, Turgut A, Tezcan A, Kantarci M. Leptomeningeal involvement in a patient with systemic lupus erythematosus infected by COVID-19. Joint Bone Spine. 2020;87(5):495.
He F, Luo Q, Lei M, et al. Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review. Clin Rheumatol. 2020;39(9):2803-2810.
Ning R, Meng S, Tang F, et al. A case of SLE with COVID-19 and multiple infections. Open Med. 2020;15(1):1054-1060.
Wen J, Suo H, Zhang Y, Tao J. Risk of COVID-19 infection among lupus erythematosus patients and rheumatoid arthritis patients: a retrospective study in Hubei, China. Eur J Dermatol. 2020;30(6):751-753.
Mathian A, Mahevas M, Rohmer J, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis. 2020;79(6):837-839.
Lawson EF, Trupin L, Yelin EH, Yazdany J. Reasons for failure to receive pneumococcal and influenza vaccinations among immunosuppressed patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2015;44(6):666-671.
Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med. 2004;351(22):2286-2294.
Liao Z, Tang H, Xu X, Liang Y, Xiong Y, Ni J. Immunogenicity and safety of influenza vaccination in systemic lupus erythematosus patients compared with healthy controls: a meta-analysis. PLoS One. 2016;11(2):e0147856.
Huang Y, Wang H, Wan L, Lu X, Tam WWS. Is systemic lupus erythematosus associated with a declined immunogenicity and poor safety of influenza vaccination?: A systematic review and meta-analysis. Medicine. 2016;95(19):e3637.
Lu CC, Wang YC, Lai JH, Lee TS, Lin HT, Chang DM. A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: safety and immunity. Vaccine. 2011;29(3):444-450.
Chang CC, Chang YS, Chen WS, Chen YH, Chen JH. Effects of annual influenza vaccination on morbidity and mortality in patients with systemic lupus erythematosus: a nationwide cohort study. Sci Rep. 2016;6:37817.
Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y. Vaccines and autoimmunity. Nat Rev Rheumatol. 2009;5(11):648-652.
Chakravarty EF, Michaud K, Katz R, Wolfe F. Increased incidence of herpes zoster among patients with systemic lupus erythematosus. Lupus. 2013;22(3):238-244.
Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices Centers for Disease C, Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30; quiz CE2-4.
Dooling KL, Guo A, Patel M, et al. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67(3):103-108.
Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52.
Mok CC, Chan KH, Ho LY, Fung YF, Fung WF, Woo PCY. Safety and immune response of a live-attenuated herpes zoster vaccine in patients with systemic lupus erythematosus: a randomised placebo-controlled trial. Ann Rheum Dis. 2019;78(12):1663-1668.
Guthridge JM, Cogman A, Merrill JT, et al. Herpes zoster vaccination in SLE: a pilot study of immunogenicity. J Rheumatol. 2013;40(11):1875-1880.
Stadtmauer EA, Sullivan KM, Marty FM, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124(19):2921-2929.
Berkowitz EM, Moyle G, Stellbrink H-J, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015;211(8):1279-1287.
Lehtinen M, Lagheden C, Luostarinen T, et al. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials. BMJ Open. 2017;7(8):e015867.
Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-1943.
Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143-2159.
Nitschmann S, Mallmann P. HPV vaccination prevents cervical neoplasms: FUTURE II study (Females United To Unilaterally REduce endo/ectocervical disease). Internist. 2008;49(2):238-240.
Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013;72(5):659-664.
Mok CC, Ho LY, To CH. Long-term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus. Vaccine. 2018;36(23):3301-3307.
Gardasil (human paillomavirus quadrivalent [types 6, 11, 16, 18] vaccine, recombinant): product information and supporting documents. Food and drug Administration. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/gardasil-vaccine-safety. Accessed Feb 28, 2021.
Dhar JP, Essenmacher L, Dhar R, Magee A, Ager J, Sokol RJ. The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus. Vaccine. 2017;35(20):2642-2646.
Soybilgic A, Onel KB, Utset T, Alexander K, Wagner-Weiner L. Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years. Pediatr Rheumatol Online J. 2013;11:29.
Chao C, Klein NP, Velicer CM, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med. 2012;271(2):193-203.
Gronlund O, Herweijer E, Sundstrom K, Arnheim-Dahlstrom L. Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study. J Intern Med. 2016;280(6):618-626.
Raposo A, Tani C, Costa J, Mosca M. Human papillomavirus infection and cervical lesions in rheumatic diseases: a systematic review. Acta Reumatol Port. 2016;41(3):184-190.
Tam LS, Chan AY, Chan PK, Chang AR, Li EK. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum. 2004;50(11):3619-3625.
Rezende RP, Ribeiro FM, Albuquerque EM, Gayer CR, Andrade LE, Klumb EM. Immunogenicity of pneumococcal polysaccharide vaccine in adult systemic lupus erythematosus patients undergoing immunosuppressive treatment. Lupus. 2016;25(11):1254-1259.
Pisoni C, Sarano J, Benchetrit G, et al. Antipneumococcal vaccination in patient with systemic lupus erythematosus. Medicina. 2003;63(5):388-392.
Elkayam O, Paran D, Caspi D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis. 2002;34(2):147-153.
Nagel J, Saxne T, Geborek P, et al. Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine. Lupus. 2017;26(10):1072-1081.
Sacre K, Goulenok T, Bahuaud M, et al. Impaired long-term immune protection following pneumococcal 13-valent/23-valent polysaccharide vaccine in systemic lupus erythematosus (SLE). Ann Rheum Dis. 2018;77(10):1540-1542.
Grabar S, Groh M, Bahuaud M, et al. Pneumococcal vaccination in patients with systemic lupus erythematosus: a multicenter placebo-controlled randomized double-blind study. Vaccine. 2017;35(37):4877-4885.
Elkayam O, Paran D, Burke M, et al. Pneumococcal vaccination of patients with systemic lupus erythematosus: effects on generation of autoantibodies. Autoimmunity. 2005;38(7):493-496.
Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103-1112.
Thong KM, Chan TM. Infectious complications in lupus nephritis treatment: a systematic review and meta-analysis. Lupus. 2019;28(3):334-346.
Galea S, Sisco S, Vlahov D. Reducing disparities in vaccination rates between different racial/ethnic and socioeconomic groups: the potential of community-based multilevel interventions. J Ambul Care Manage. 2005;28(1):49-59.
Wong MCS, Huang JLW, George J, et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol. 2019;16(1):57-73.